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Abstract: β-blockers are effective antihypertensive agents and, together with diuretics, have 
been the cornerstone of pioneering studies showing their benefits on cardiovascular morbidity and 
mortality as a consequence of blood pressure reduction in patients with hypertension. However, 
evidence from recent meta-analyses have demonstrated no benefit afforded by atenolol compared 
with placebo in risk of mortality, myocardial infarction, or stroke, and a higher risk of mortality 
and stroke with atenolol/propranolol compared with other antihypertensive drug classes. Thus, 
the effect of these agents on cardiovascular morbidity and mortality in hypertensive patients, 
especially their use in uncomplicated hypertension, has remained largely controversial. However, 
it is recognized that the clinical studies used in these meta-analyses were mainly based on the 
older second-generation β-blockers, such as atenolol and metoprolol. Actually, considerable 
heterogeneity in, eg, pharmacokinetic, pharmacological, and physicochemical properties exists 
across the different classes of β-blockers, particularly between the second-generation and 
newer third-generation agents. Carvedilol is a vasodilating noncardioselective third-generation 
β-blocker, without the negative hemodynamic and metabolic effects of traditional β-blockers, 
which can be used as a cardioprotective agent. Compared with conventional β-blockers, carve-
dilol maintains cardiac output, has a reduced prolonged effect on heart rate, and reduces blood 
pressure by decreasing vascular resistance. Studies have also shown that carvedilol exhibits 
favorable effects on metabolic parameters, eg, glycemic control, insulin sensitivity, and lipid 
metabolism, suggesting that it could be considered in the treatment of patients with metabolic 
syndrome or diabetes. The present report provides an overview of the main clinical studies 
concerning carvedilol administered as either monotherapy or in combination with another 
antihypertensive or more frequently a diuretic agent, with particular focus on the additional 
benefits beyond blood pressure reduction.
Keywords: carvedilol, β-blocker, hypertension, diabetes, atherosclerosis
Introduction
Arterial hypertension is a major risk factor for stroke, coronary events, and renal 
failure.1–3 Current estimates suggest that over 70 million adults in the United States 
and approximately one billion adults worldwide have hypertension.4,5 These poor 
figures can be attributed to undetected hypertensive patients (blood pressure [BP] 
never previously measured), known but untreated hypertension, and known hyperten-
sive patients with low adherence to both antihypertensive drug therapies and lifestyle 
recommendations.4,6
Due to the need to obtain BP normalcy, guidelines published by the European 
Society of Hypertension/European Society of Cardiology recommend initiation of 
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monotherapy in patients with baseline first-degree arterial 
hypertension, mild/moderate global cardiovascular risk, or 
a target BP , 140/90 mmHg, while combination therapy is 
suggested in patients with baseline second-degree or more 
arterial hypertension, high or very high global cardiovas-
cular risk, or a target BP , 130/80 mmHg. Combination 
therapy is particularly recommended when monotherapy 
fails to reach BP goals or in patients at high global cardio-
vascular risk.1–3
For the past four decades, β-blockers have been used 
to treat hypertension.7,8 These agents have been shown to 
reduce cardiovascular-related mortality in clinical trials, 
and following these observations, both the European Soci-
ety of Hypertension/European Society of Cardiology and 
JNC-7 guidelines recommend use of β-blockers as first-line 
or second-line antihypertensive agents.1–3
However, in recent years the use of β-blockers (especially 
for uncomplicated hypertension) has been controversial and 
widely debated.9–12 This has been mainly due to the findings 
from meta-analyses and clinical trials demonstrating a lack 
of benefit from β-blockers compared with placebo or other 
antihypertensive agents.13–19 Following this, the National 
Institute for Health and Clinical Excellence hypertension 
guidelines in the UK downgraded the use of β-blockers 
from first-line agents for hypertension to fourth-line add-on 
therapy.20,21 More recent National Institute for Health and 
Clinical Excellence guidelines state that β-blockers are 
not a preferred initial therapy for hypertension, but may be 
considered in younger people, particularly those with an 
intolerance or contraindication to angiotensin-converting 
enzyme inhibitors and angiotensin II receptor blockers, 
women of child-bearing potential, and people with evidence 
of increased sympathetic drive.22
Although conclusions drawn from these meta-analyses 
and later incorporated into the hypertension guidelines appear 
to cast β-blockers in a poor light, it needs to be pointed out 
that there were some limitations in these studies that may 
in part account for the poor effects observed. Atenolol was 
used in many of these studies as a once-daily dose, whereas 
ideally it should be taken more frequently, based on its 
pharmacokinetic properties.23 In addition, the majority of 
trials included elderly patients, who are recognized to be not 
as responsive to β-blockers as younger patients.24 However, 
the major critical weakness lies in the fact that most of the 
studies included older “traditional” agents (eg, propranolol 
and atenolol) that have no vasodilatory effects. This obser-
vation is extremely important, given that β-blockers are not 
a homogeneous class and exert markedly different effects 
according to their individual physicochemical and pharma-
cological characteristics.20
In fact, current JNC-7 guidelines recommend use of 
β-blockers for the initial treatment of patients with stage 
1 hypertension and compelling indications, eg, previous 
myocardial infarction, ischemic heart disease, heart failure, 
  diabetes, or high risk of coronary artery disease.1 Furthermore, 
β-blockers are also recommended for initial treatment in 
patients with stage 1 hypertension without compelling 
indications and in patients with stage 2 hypertension who 
require a combination of drugs to achieve BP control.1
Third-generation vasodilating β-blockers such as celiprolol, 
carvedilol, and nebivolol, do not possess some of the unfavor-
able effects often associated with other β-blocker compounds.3 
These newer drugs reduce BP as well if not better than other 
antihypertensive agents.25,26 It is also recognized that vasodilating 
β-blockers have a favorable metabolic and tolerability profile 
compared with older traditional β-blockers.7,27,28 Furthermore, 
both carvedilol and nebivolol have been used in outcome studies 
of chronic heart failure and were shown to reduce the primary 
endpoint of mortality and hospitalization.29
With regard to carvedilol, the antihypertensive and ancil-
lary benefits conferred by this vasodilating β-blocker are worth 
highlighting. Compared with other antihypertensive drugs, 
carvedilol has been shown to achieve superior or comparable 
BP reduction in hypertensive patients, whether administered as 
monotherapy (25 mg/day)25,26,30 or in combination with another 
antihypertensive agent, such as a diuretic.31,32   Additional 
benefits afforded by carvedilol include: its use in specific 
hypertensive patients at risk of coronary artery disease, where it 
has been shown to increase coronary flow reserve;33,34 the post-
myocardial infarction setting, where carvedilol is indicated;35 
and in patients with diabetes or metabolic syndrome, in 
whom carvedilol has favorable metabolic characteristics36 in 
addition to providing renal protection.37,38 This review article 
summarizes the main findings from clinical studies examining 
the pharmacologic and metabolic properties of carvedilol in 
hypertension and concomitant diseases.
Mode of action
Carvedilol is a racemic mixture of (±)-1-(carbazol-4-
yloxy)-3-[[2-(o-methoxyphenoxy) ethyl]amino]-2-propanol 
(Figure 1). It is a lipophilic vasodilating noncardioselective 
β-blocker which lacks intrinsic sympathomimetic activity, 
thus having improved tolerability compared with older 
β-blockers.28,39 Carvedilol is absorbed rapidly following oral 
administration and is extensively metabolized in the liver.40 
The older generation “traditional” β-blockers selectively 
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antagonize β1-adrenergic receptors or antagonize both 
β1-adrenergic and β2-adrenergic receptors.41 They also 
reduce BP mainly through a reduction in cardiac output, while 
systemic vascular resistance remains largely unchanged.9 
In contrast, carvedilol blocks norepinephrine binding to 
α1-adrenergic receptors in addition to both β1-adrenergic and 
β2-adrenergic receptors.28,39,42 This results in a reduction in 
arterial BP by maintaining cardiac output and decreasing total 
β-adrenoreceptor vasoconstrictor tone.9,43 Therefore, as can be 
seen in Table 1, the hemodynamic effect exerted by carvedilol 
is similar to that of angiotensin-converting enzyme inhibitors 
and markedly superior to that of traditional β-blockers.
In addition to its BP-reducing effects, carvedilol also has 
a superior metabolic profile in terms of lipid and glucose 
metabolism compared with traditional β-blockers44 (Table 1). 
This specific effect is addressed in further detail later in this 
review. In addition, carvedilol also exerts antioxidant effects 
attributable to stimulation of nitric oxide production, as well 
as having anti-inflammatory effects.39,45,46
BP-lowering as monotherapy
Regardless of the drug employed, monotherapy allows 
achievement of BP target values in a limited number of 
hypertensive patients.2,3 Carvedilol is indicated for the 
treatment of essential hypertension. It can be administered 
alone or in combination with other antihypertensives, par-
ticularly with a thiazide diuretic.
Early studies have shown that single administration of 
carvedilol 25–50 mg results in a consistent reduction in 
BP over 24 hours compared with placebo, confirming its 
activity throughout daily activity and sleeping periods.47,48 
Approximately 90% of the peak reduction in BP is observed 
at the time of the next dose.
In addition, clinical studies have shown that carvedilol 
25 mg once daily decreases arterial BP to a greater extent than 
the traditional β-blocker, atenolol, in patients with moderate 
and essential hypertension, respectively.49,50
Furthermore, comparative studies have also shown that 
carvedilol reduces BP to a similar extent as other antihyper-
tensive drugs in patients with essential hypertension. A review 
by Moser et al reported data from three different studies with 
carvedilol compared with captopril, an angiotensin-converting 
enzyme inhibitor, slow-release nifedipine, a long-acting cal-
cium channel blocker, and hydrochlorothiazide, a diuretic.51 
The extent of BP reduction with carvedilol was similar to that 
achieved by comparator drugs (Figure 2A).
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Figure 1 Chemical structure of carvedilol.
Table 1 Effects of different antihypertensive drugs in hypertensive patients
Parameter Ideal  
drug
ACEI  
or ARB
Carvedilol α1-adrenoceptor 
blocker
DHP calcium 
antagonist
Traditional 
β-blockers
Thiazide 
diuretic
MAP ↓ ↓ ↓ ↓ ↓ ↓ ↓
TPR ↓ ↓ (↓) ↓ ↓ (↑) ↓
Cardiac output 0 0 0 0 0 (↓) 0
Heart rate 0/↓ 0 ↓ (↑) (↑) ↓ 0
SNS activation ↓ ↓ ↓ (↑) ↑ ↓ ↑
RAS ↓ ↓ ↓ 0 ↑ ↓ ↑
Lipid metabolism 0/+ 0/+ 0 0/+ 0 - -
Glucose metabolism 0/+ 0 0 0 0 - -
Notes: Effects are color-coded where white represents positive effect whereas black represents negative effects and light grey and dark grey represent slight positive and 
slight negative effects respectively. Data drawn from Messerli FH, Grossman E. Beta-blockers in hypertension: is carvedilol different? Am J Cardiol. 2004;93 Suppl:7B–12B.9
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DHP, dihydropyridine; MAP, mean arterial blood pressure; SNS, 
sympathetic nervous system; RAS, renin-angiotensin system; TPR, total peripheral resistance; ↑, increase (activation); ↓, decrease (inhibition); 0, no effect; +, positive effect;   
-, negative effect; ( ), predominantly after acute administration.
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Figure 2 Antihypertensive effect of carvedilol compared with captopril, slow-release nifedipine, hydrochlorothiazide, and nebivolol. (A) Carvedilol was administered at 25–50 mg 
once daily. Captopril was administered at 25–50 mg twice daily. Slow-release nifedipine was administered at 20–40 mg twice daily and hydrochlorothiazide was administered 
at 25–50 mg once daily. Reprinted by permission from Macmillan Publishers Ltd: American Journal of Hypertension. Moser M, Frishman w. Results of therapy with carvedilol, 
a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens. 1998;11(1 Pt 2):15S–22S. Copyright 1998.51 (B) Antihypertensive effect of 
carvedilol 5 mg/day versus nebivolol 5 mg/day. Copyright (c) 2011, Aves Yayincilik. Adapted with permission from Erdoğan O, Ertem B, Altun A. Comparison of antihypertensive 
efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial. Anadolu Kardiyol Derg. 2011;11(4):310–313. Turkish.30
Notes: P values represent significant differences compared with placebo (for either carvedilol or nebivolol) for mean systolic and diastolic blood pressure. Filled bars 
represent systolic blood pressure and open bars represent diastolic blood pressure.
Abbreviations: SR-Nifedip, slow-release nifedipine; Carved, carvedilol; HCTZ, hydrochlorothiazide.
In addition, a more recent clinical trial examined the 
antihypertensive effect of carvedilol 25–50 mg/day compared 
with another calcium channel blocker, amlodipine, at 
5–10 mg/day in patients with mild-to-moderate hypertension.26 
Both drugs reduced systolic and diastolic BP in a dose-
dependent manner, and although amlodipine reduced systolic 
BP to a greater extent, the reduction in diastolic BP was 
similar for both agents. These findings suggest that carvedilol 
can be considered as an alternative option for the treatment 
of mild-to-moderate hypertension. Although carvedilol has 
a clearcut advantage over traditional β-blockers in terms of 
BP reduction, these hemodynamic effects also rival those of 
nebivolol, another third-generation vasodilatory β-blocker. 
The antihypertensive effect was examined between carvedilol 
25 mg/day and nebivolol 5 mg/day in patients with mild-to-
moderate hypertension.30 Patients experienced a significant 
reduction in both systolic and diastolic BP on carvedilol or 
nebivolol compared with placebo (P , 0.05, Figure 2B). 
No significant difference was observed in the extent of BP 
reduction between carvedilol and nebivolol (Figure 2B). 
Collectively, these clinical studies show that once-daily 
administration of carvedilol 25 mg as monotherapy provides 
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a reduction in BP that is equivalent to, if not better than, other 
antihypertensive agents.
BP-lowering in combination therapy
Although it can now be seen that carvedilol is an effective 
antihypertensive agent when administered as monotherapy, it 
is most frequently administered in combination with another 
antihypertensive agent, such as a diuretic. In fact, both the 
European and JNC-7 guidelines recommend combination 
therapy, especially when monotherapy fails to reach BP goals 
or in patients at high cardiovascular risk.1–3
Over 20 years ago, a small double-blind comparative trial 
conducted in 126 patients with mild-to-moderate hyperten-
sion showed that long-term administration of carvedilol 
25 mg/day decreased BP to a greater extent than atenolol 
50 mg/day. However, a combination of either of these drugs 
with hydrochlorothiazide produced an additive and equivalent 
response.31 This additive effect was also observed to a similar 
extent by the same authors in different patients (n = 122), this 
time pretreated with hydrochlorothiazide 25 mg for 4 weeks 
and then given atenolol 50 mg/day or carvedilol 25 mg/day.49 
Both carvedilol and atenolol were safe when given alone or 
in combination with hydrochlorothiazide.
This additive effect was also observed in other studies. 
A single-blind single-center study examined the short-
term efficacy and safety of adding carvedilol 25 mg/day 
to hydrochlorothiazide 25 mg/day in patients inadequately 
treated with hydrochlorothiazide alone.52 After 7 days of 
combined treatment, 53% of patients achieved diastolic 
BP levels , 90 mmHg and 93% of patients achieved BP 
levels , 95 mmHg. Furthermore, another clinical trial has 
investigated the antihypertensive effect of the carvedilol–
hydrochlorothiazide combination in 26 severely hypertensive 
patients.53 Initially patients were inadequately treated with 
hydrochlorothiazide (diastolic BP . 120 mmHg); however, 
after 8 weeks of daily administration of carvedilol (10 mg 
or 20 mg) on an outpatient basis, both systolic and diastolic 
BP were significantly decreased (P , 0.001 for both). No 
patient experienced bradycardia, and carvedilol was generally 
well tolerated.
Overall, these studies demonstrate that carvedilol 
10–25 mg once daily in combination with hydrochlorothi-
azide is an effective and safe therapeutic option for patients 
with mild-to-moderate or severe hypertension. In addition to 
hydrochlorothiazide, the BP-lowering effect of carvedilol has 
also been examined in combination with the third-generation 
vasodilatory β-blocker, nebivolol.54 This retrospective study 
examined the effect of atenolol 50–100 mg/day, a carvedilol-
nebivolol combination (25 + 25 mg/day and 5 mg/day, 
respectively) and patients chronically treated with angiotensin 
II receptor blockers.54 The findings of this study revealed 
that patients treated with angiotensin II receptor blockers or 
the carvedilol-nebivolol combination were associated with 
lower central systolic BP than atenolol treatment, suggest-
ing that, like angiotensin II receptor blockers, vasodilating 
β-blockers can exert more favorable central hemodynamic 
effects than atenolol.
Effects on lipid metabolism
Previous studies have shown that traditional β-blockers can 
have detrimental effects on serum lipids, including increas-
ing triglycerides and decreasing high-density lipoprotein 
levels.9,55–58 Carvedilol, on the other hand, has been shown 
to have a neutral or beneficial effect on lipoprotein lipase 
activity and levels of triglycerides and high-density lipopro-
tein cholesterol9,59 (Figure 3).
These favorable effects on lipid metabolism were con-
firmed later in the GEMINI (Glycemic Effects in Diabetes 
Mellitus: Carvedilol-Metoprolol Comparison in Hyperten-
sives) trial, a large (n = 1235) randomized, double-blind 
comparison of the effect of carvedilol versus metoprolol 
in hypertensive diabetic patients. This study showed that 
patients treated with carvedilol had decreased low-density 
lipoprotein cholesterol, but not with metoprolol, and triglyc-
eride levels were not increased, as with metoprolol.36,60
Another comparative randomized trial examined the effect 
of once-daily extended-release carvedilol or extended-release 
metoprolol in hypertensive patients without diabetes and 
not requiring lipid-lowering therapy.61 Although there was 
no difference in the effect of the two drugs on high-density 
lipoprotein or BP, triglyceride levels were increased by 
metoprolol but not by carvedilol. This differential metabolic 
profile could be important in determining treatment options 
in this patient group.
A recent review article examined 12 published studies and 
case reports that evaluated the impact of carvedilol on lipid 
profile.62 Although it was clear that β1-selective antagonists 
worsen the lipid profile compared with carvedilol, it remained 
unclear as to whether carvedilol independently improves or 
has a neutral effect on lipid profile. Regardless, carvedilol 
should still be considered a favorable choice for the treat-
ment of patients with heart failure and/or hypertension with 
dyslipidemia.
Effects in diabetes
It is well recognized that conventional β-blockers exert nega-
tive effects on glucose control and insulin sensitivity, while 
also increasing the risk of new-onset diabetes in hypertensive 
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patients.9,18,63 However, earlier studies with β-blockers having 
vasodilatory properties have shown beneficial effects on 
glycemic control and insulin sensitivity.64,65 More recently, 
the effects of carvedilol and atenolol were examined in hyper-
tensive patients with type 2 diabetes. This study demonstrated 
that after 24 weeks of treatment, fasting plasma glucose and 
glycosylated hemoglobin (HbA1c) were decreased and insulin 
sensitivity was increased with carvedilol, whereas atenolol 
had the opposite results59 (Figure 4).
Furthermore, in COMET (Carvedilol or Metoprolol 
European Trial), the risk for new-onset diabetes was 22% 
lower in patients receiving carvedilol than those receiving 
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Figure 3 Comparison of the effects of carvedilol and atenolol on lipid parameters in patients with hypertension. P values represent significant differences in HDL cholesterol 
(B) and triglycerides (C) between carvedilol and atenolol treatment; the difference for total cholesterol was not significant (A). Open bars represent baseline and filled bars 
represent the 6-month time point.
Notes: Data values are also presented. Carvedilol was administered at 25 mg once daily (n = 23) and atenolol was administered at 50 mg once daily (n = 22). Copyright (c) 1997, 
American College of Physicians–American Society of Internal Medicine. Adapted with permission from Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular 
effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997:126(12):955–959.59
Abbreviation: HDL, high-density lipoprotein.
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metoprolol.66 The effects of carvedilol were next examined in 
a large comparative trial in patients with type 2 diabetes. In the 
GEMINI trial, the effect of carvedilol treatment was compared 
with metoprolol in 1235 patients with hypertension and type 2 
diabetes.36,67 At the end of the study, carvedilol lowered systolic 
and diastolic BP to the same extent as metoprolol.36 However, 
the discontinuation rate because of poor glycemic control was 
2.2% with metoprolol but only 0.6% with carvedilol (P , 0.04). 
Furthermore, carvedilol had no adverse effect on HbA1c val-
ues.67 While nonvasodilating β-blockers are often associated 
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Figure 4 Comparison of the effects of carvedilol and atenolol on metabolic parameters in patients with hypertension. P values represent significant differences in metabolic 
parameters (A–C) between carvedilol and atenolol treatment. Open bars represent baseline and filled bars represent the 6-month time point.
Notes: Data values are also presented. Carvedilol was administered at 25 mg once daily (n = 23) and atenolol was administered at 50 mg once daily (n = 22). Copyright (c) 1997, 
American College of Physicians–American Society of Internal Medicine. Adapted with permission from Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular 
effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997:126(12):955–959.59
Abbreviation: HbA1c, glycosylated hemoglobin.
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with undesirable effects on insulin sensitivity and masking of 
symptoms of hypoglycemia in this patient population, findings 
from the GEMINI study suggest that carvedilol does not share 
these negative effects. It is also worth noting that the progres-
sion to microalbuminuria was less frequent with carvedilol 
than with metoprolol (6.4% versus 10.3%; odds ratio 0.60; 95% 
confidence interval: 0.36–0.97; P = 0.04). This difference may 
be due to an improvement in insulin resistance or to an effect 
on oxidant stress by carvedilol.59
Many of these earlier comparative studies were included 
(from the period of 1980–2008) in a recent schematic 
review that examined the effect of both nonvasodilating and 
vasodilating β-blockers (including carvedilol) on glucose, 
metabolic, and lipid parameters.27 The main findings from 
this analysis demonstrated that vasodilatory β-blockers were 
associated with more favorable effects on glucose and lipid 
profiles than nonvasodilating β-blockers.
More recently, a clinical trial has examined the effect 
of metoprolol versus carvedilol on endothelial function 
and insulin-stimulated endothelial function in patients with 
type 2 diabetes.44 Insulin-stimulated endothelial function 
deteriorated after treatment with metoprolol, whereas there 
was no change with carvedilol. This study demonstrated 
that vascular insulin sensitivity was preserved in diabetic 
patients treated with carvedilol but blunted during treatment 
with metoprolol.44
Effects in metabolic syndrome
In  addition  to  diabetic  patients,  carvedilol  is  also 
recognized to have beneficial effects in patients with   
metabolic syndrome.68 A recent randomized comparative 
study examined the effect of carvedilol versus atenolol 
or doxazosin for 3 months in 77 patients with metabolic 
  syndrome.69 At the end of the study period, a similar reduction 
in both systolic and diastolic BP was observed for all three 
treatment groups. Furthermore, no significant differences were 
observed between the three groups for a range of biochemical 
parameters, including plasma glucose, uric acid, urea, 
cholesterol (total and low-density lipoprotein), triglycerides, 
apoproteins, insulin, HbA1c, and homeostasis model 
assessment-insulin resistance (HOMA-IR). However, only 
carvedilol did not alter low-density lipoprotein levels (percent 
change for doxazosin -5.6 ± 13.5 and atenolol -8 ± 9.8 versus 
carvedilol -0.1 ± 12.2, respectively; P , 0.05).69 Furthermore, 
these favorable effects of carvedilol were observed on other 
parameters (in addition to reduction in BP) that identify the 
metabolic syndrome, such as reduction in waist circumfer-
ence, body mass index, and fasting blood glucose (Figure 5). 
It is worth noting that the effects of atenolol on insulin sensitiv-
ity may be attributed, in part, to the lower insulin levels and 
higher HbA1c levels in this group than in the other treatment 
groups.69 Furthermore, differences in the glucose-lowering 
and insulin-lowering effects of atenolol between the studies by 
Giugliano et al (Figure 4) and Uzunlulu et al (Figure 5) may 
be due to the aforementioned differences in baseline insulin 
and HbA1c levels, as well as the additional counseling on diet 
and exercise received by these patients.59,69
Although renin-angiotensin system inhibitors are recom-
mended for the management of hypertensive patients with 
metabolic syndrome, head-to-head trials examining these 
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agents against carvedilol are lacking. Overall, the evidence 
underscores the benefits of carvedilol and suggests that this 
drug should be considered as a promising therapeutic option 
in hypertensive patients with metabolic syndrome.
Effect on left-ventricular 
hypertrophy
Development of left-ventricular hypertrophy (LVH) in 
hypertensive patients is associated with an increased risk 
of cardiovascular mortality and morbidity.70 Although there 
is evidence that the older traditional β-blockers are not as 
effective at reducing LVH as other drug classes,71,72 these 
early studies did not examine vasodilatory β-blockers like 
carvedilol or nebivolol. Therefore, it is plausible that the 
α-blocking effect of carvedilol may provide superior ben-
efit in terms of LVH regression, compared with traditional 
β-blockers. In fact, there are several preclinical and clinical 
studies available to suggest that carvedilol may be effective 
in the regression of LVH.73–75 In particular, the study by 
Verza et al examined the effect of 6 months of daily therapy 
with carvedilol 25 mg on LVH in elderly patients (mean age 
69 years) with essential hypertension and LVH.74 Carvedilol 
caused a significant reduction in systolic and diastolic BP 
(Figure 6A) and LVH, as measured by left ventricular mass 
in addition to left ventricular mass index (Figure 6B).
In addition, a clinical trial evaluated the independent and 
combined effects of captopril and carvedilol on left ven-
tricular remodeling in chronic heart failure in 57 patients.76 
Although angiotensin-converting enzyme inhibitor therapy 
did not alter left ventricular volume, treatment with carvedilol 
was associated with a reduction in chamber volume. Both 
drugs reduced left ventricular mass and sphericity. These 
beneficial effects on remodeling may help explain the rela-
tive prognostic benefits of these therapies.
Effect on coronary flow reserve
It is recognized that patients with LVH have lower coronary 
flow reserve, and there is evidence demonstrating that carve-
dilol can increase coronary flow reserve in these patients.33,77 
A study performed in 63 hypertensive patients with LVH 
showed that carvedilol, but not metoprolol, increased coro-
nary flow reserve in addition to decreasing left-ventricular 
mass index33 (Figure 7A).
Further, three clinical studies clearly confirm the benefi-
cial effect of carvedilol therapy for 1–6 months on coronary 
flow reserve (Figure 7B),78–80 the magnitude of this benefit 
(absolute increase in coronary flow reserve) being greater 
than in three studies that examined the effect of nebivolol 
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on coronary flow reserve (Figure 7C).81–83 This improvement 
in coronary blood flow strongly suggests the use of vasodi-
lating β-blockers, such as carvedilol, in patients at risk of 
atherosclerosis or coronary artery disease.34
Following myocardial infarction
Previous trials have shown benefit in patients receiving 
β-blocker therapy following myocardial infarction.35,84–87 
The American Heart Association guidelines recommend that 
patients without a clear contraindication to β-blocker therapy 
should receive β-blockers within a few days of myocardial 
infarction and continue them indefinitely.88,89 Likewise, both 
the JNC-7 and European Society of Hypertension/European 
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Society of Cardiology guidelines recommend β-blockers 
(as well as other antihypertensive agents) in hypertensive 
patients after myocardial infarction.1–3 The CAPRICORN 
(Carvedilol Post-Infarct Survival Control in Left Ventricular 
Dysfunction) trial was specifically designed to examine the 
benefits afforded by carvedilol in patients with left ventricular 
systolic dysfunction following acute myocardial infarction.35 
Although the primary endpoint of this trial failed to reach 
statistical significance (all-cause mortality or cardiovascular 
hospitalization), all-cause mortality alone was significantly 
lower in the carvedilol group than in the placebo group 
(116 [12%] versus 151 [15%]; 95% confidence interval: 
0⋅77 [0⋅60–0⋅98], P = 0.03) and confirmed data from other 
studies. Based on findings from this trial, the guidelines now 
indicate carvedilol in this patient group. A recent Norwegian 
trial compared the antioxidative effects of carvedilol and 
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atenolol in 232 patients with acute myocardial infarction.90 
The findings of this study showed that carvedilol had a more 
pronounced antioxidative effect than atenolol in post-acute 
myocardial infarction patients. Together, these studies show 
that carvedilol is effective and superior to other β-blockers 
in the treatment of patients following acute myocardial 
infarction.
Regression of atherosclerosis
Carvedilol is known to have many effects which are directly 
linked to prevention of atherosclerosis. Carotid internal-
medial thickness (CIMT) has been shown to be directly 
associated with changes in morning BP. Therefore, carotid 
atherosclerosis may be prevented by control of morning BP. 
In a randomized controlled trial performed in 128 hyperten-
sive patients, treatment with carvedilol for 12 months was 
shown to decrease morning BP significantly (Figure 8).91 
Furthermore, in this study, it was observed that CIMT regres-
sion occurred in 49% of patients treated with carvedilol 
compared with only 18% of patients treated with metoprolol 
(P , 0.01).91
Matrix metalloproteinase (MMP) is also critical for ath-
erosclerosis formation after vascular injury, and carvedilol, 
a pharmacological antioxidant, is able to inhibit the expres-
sion of MMP-2 and MMP-9 both in vivo and in vitro. This 
points towards a potential clinical indication for carvedilol 
in the prevention of atherosclerosis.92 Antioxidant and anti-
inflammatory actions and an ability to decrease the rate of 
apoptosis of smooth muscle cells are additional features 
of carvedilol which, collectively, are able to stabilize ath-
erosclerotic plaques.45,93 An early sign of atherogenesis 
is endothelial adhesiveness to human mononuclear cells, 
induced by tumor necrosis factor-alpha, which has been 
shown to be reduced by carvedilol by inhibiting production 
of intracellular reactive oxygen species, activation of tran-
scription factors, and increasing expression of vascular cell 
adhesion protein-1 and E-selectin, suggesting its potential 
role in clinical atherosclerosis.94 Although accumulating 
evidence suggests a clinically relevant antiatherogenic role 
for carvedilol, clinical trials with well defined endpoints are 
needed to confirm these preliminary findings.
Kidney disease
Current opinion favors the use of β-blockers in patients with 
chronic kidney disease.95 In fact, a recent meta-analysis 
of eight studies (n = 5972) showed that β-blocker therapy 
improved all-cause mortality in patients with chronic kidney 
disease and chronic systolic heart failure, reinforcing the use 
of these agents in this group.96 With regard to carvedilol, 
there is also evidence indicating that this agent exerts reno-
protective effects. Earlier studies showed beneficial effects 
on renal hemodynamics, including decreased renal vascular 
resistance, in patients with heart failure, despite decreasing 
systemic BP.97 Carvedilol has also been shown to decrease 
both systolic and diastolic BP without decreasing renal blood 
flow or glomerular filtration rate, while reducing renal vas-
cular resistance.98 Few studies have examined the effects of 
carvedilol on renal function or clinical outcomes in patients 
with heart failure and renal dysfunction. However, in one 
comparative study, metoprolol was observed to decrease 
estimated glomerular filtration rate significantly, but this 
did not change in those who received carvedilol.99 A meta-
analysis performed on the CAPRICORN and COPERNICUS 
(Carvedilol Prospective Randomized Cumulative Survival) 
trials including 4217 patients35,100 suggests that the benefits 
of carvedilol therapy in patients with left ventricular systolic 
dysfunction with or without symptoms of heart failure are 
consistent even in the presence of mild to moderate chronic 
kidney disease.101 Actually, in individuals without chronic 
kidney disease, the use of carvedilol in the long-term has 
been shown to improve symptoms of heart failure, increase 
left ventricular ejection fraction, mitigate neurohormonal 
activation and peripheral vasoconstriction, and decrease 
sympathetic overactivity, as well as decrease salt and water 
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retention.102,103 In contrast with traditional β-blockers, several 
trials have demonstrated a beneficial effect of carvedilol on 
kidney function in terms of increased renal blood flow and a 
reduction in microalbuminuria.37,38,104,105 In addition, among 
patients with normal urine albumin excretion at baseline in 
the GEMINI trial, fewer treated with carvedilol progressed to 
microalbuminuria than those treated with metoprolol (6.4% 
versus 10.3%, respectively).36 It is tempting to speculate 
that carvedilol may vasodilate efferent arterioles, but defini-
tive evidence is not yet available to confirm this. Overall, 
these findings support a beneficial role for carvedilol on 
renal function. To assess these renoprotective effects fully, 
randomized controlled trials with well defined endpoints are 
needed in patients with nephropathy.
Additional pleiotropic effects
In addition to the recognized BP-lowering and favorable 
metabolic effects of carvedilol in a broad range of hyperten-
sive patients, recent preclinical and clinical studies indicate 
that carvedilol exerts other pleiotropic effects. Although it 
is recognized that carvedilol is effective in the treatment of 
patients following acute myocardial infarction,35 few studies 
have compared the additive effects of carvedilol and renin-
angiotensin system inhibitors. A clinical study retrospectively 
investigated 251 patients with acute myocardial infarction 
treated with angiotensin-converting enzyme inhibitors or 
angiotensin II receptor blockers and divided them into two 
groups, ie, those treated without β-blockers (n = 80) and those 
treated with β-blockers (β-blocker group, n = 171; carvedilol 
or bisoprolol, n = 80).106 After one year of follow-up, it was 
found that both survival and cardiac event-free rates in the 
β-blocker group were significantly higher than in the group 
not treated with β-blockers. Although the percent change in 
BP did not significantly differ between the two groups, levels 
of brain natriuretic peptide, MMP-2, and MMP-9, and left 
ventricular ejection fraction improved significantly in the 
β-blocker group. Furthermore, treatment with carvedilol 
achieved more favorable outcomes than bisoprolol. This 
study demonstrates that β-blocker therapy combined with 
a renin-angiotensin system inhibitor is more effective than 
treatment with a renin-angiotensin system inhibitor alone in 
patients with acute myocardial infarction.
Carvedilol has also been shown to inhibit neointimal 
hyperplasia in patients with coronary artery disease. The 
effects of carvedilol-loaded stents compared with bare 
metal stents on clinical outcomes at 2 years was examined 
in patients with coronary artery disease.107 Patients receiving 
carvedilol-coated stents had an increased luminal area and 
reduced neointimal thickening compared with patients 
receiving bare metal stents. These findings demonstrate 
that carvedilol-loaded stents can inhibit neointimal hyper-
plasia without increased risk of cardiac death, myocardial 
infarction, or stent thrombosis at 2-year follow-up.
Tolerability
β-blockers are traditionally associated with side effects 
including depression, fatigue, sexual dysfunction, and cold 
extremities.108 However, evidence is available from several 
studies indicating that carvedilol has a good tolerability 
profile. For example, carvedilol therapy was observed to 
be safe in patients with Duchenne’s or Becker’s muscular 
dystrophy, in addition to producing a modest improvement 
in systolic and diastolic function.109 Results from the SAT-
ELLITE survey demonstrated that initiation and uptitration 
of carvedilol in ambulatory care patients with chronic heart 
failure was feasible and safe.110 In this survey, the efficacy 
and tolerability of carvedilol were at least as good as in the 
clinical trials, while amelioration of patient well being was 
significant despite suboptimal dosing. In pediatric patients, 
carvedilol also appears to be well tolerated. Pediatric patients 
with chronic heart failure who were not responding to stan-
dard therapy benefited from treatment with oral carvedilol, 
although, because of increased elimination of carvedilol, an 
age-appropriate optimized carvedilol dosing strategy was 
used.111,112 The safety and efficacy of carvedilol has also been 
examined in very elderly diabetic patients with heart failure. 
However, beta-blockers are usually prescribed with caution 
in these patients because of their perceived unfavorable 
effects on glucose metabolism, regardless of evidence of their 
effectiveness and safety in middle-aged diabetic patients. 
In a recent study of elderly diabetic patients, no worsening 
of fasting glucose, HbA1c or creatinine levels, or increased 
incidence of deaths and hospitalizations was observed in 
elderly diabetics treated with carvedilol.113
Furthermore, carvedilol appears to be well tolerated in 
elderly patients with chronic heart failure, although the very 
elderly (.80 years) tolerate carvedilol less well than their 
younger counterparts (70–79 years). Regardless, carvedilol 
was tolerated in more than 76% of elderly patients with 
chronic heart failure at a dose higher than the starting dose. 
Therefore, the elderly with chronic heart failure should not 
be denied treatment with carvedilol due to concerns regard-
ing tolerability.114 Other studies which have investigated 
the tolerability of carvedilol in the elderly all conclude that 
this drug can be administered safely in this age group.115–119 
Overall, these studies indicate that carvedilol has an excellent 
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tolerability profile across a wide range of patient types, thus 
improving the potential for compliance.
Conclusion
This report provides compelling evidence for the use of 
carvedilol as an antihypertensive agent in a wide range of 
hypertensive population types. Current JNC-7 guidelines 
recommend use of β-blockers such as carvedilol for initial 
treatment of patients with stage 1 hypertension and compel-
ling indications, eg, previous myocardial infarction, ischemic 
heart disease, heart failure, diabetes, or high risk of coronary 
artery disease.1 β-blockers are also recommended for initial 
treatment of patients with stage 1 hypertension without 
compelling indications and in patients with stage 2 hyper-
tension who require a combination of drugs to achieve BP 
control.1,120
Carvedilol, a vasodilating noncardioselective β-blocker, 
allows the opportunity to use a cardioprotective agent with-
out the concerning hemodynamic and metabolic effects 
associated with traditional β-blocker therapy. In contrast 
with classical β-blockers, carvedilol maintains cardiac 
output, has a reduced effect on heart rate, and decreases BP 
mainly by decreasing vascular resistance. Studies compar-
ing carvedilol with conventional β-blockers have shown 
that carvedilol has greater benefit in terms of BP-lowering 
effects whether administered as monotherapy or combined 
with a diuretic or renin-  angiotensin system inhibitor, in 
addition to improving glycemic control, insulin sensitivity, 
and lipid metabolism, suggesting that it could be used in 
subjects with metabolic syndrome or diabetes. Further-
more, the evidence shows that carvedilol can improve 
LVH and coronary flow reserve, in addition to reducing 
progression of atherosclerosis and neointimal hyperplasia 
in patients with coronary artery disease. Carvedilol is also 
currently indicated in the post-myocardial infarction set-
ting. These distinct multifaceted hemodynamic and meta-
bolic features specific to carvedilol could result in potential 
beneficial effects in other likely concomitant diseases, such 
as renal disease and peripheral vascular disease. To assess 
these further effects fully, randomized controlled trials with 
well defined endpoints in specific patient populations with 
underlying hypertension are now required.
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